Waldenström's macroglobulinemia surgery: Difference between revisions
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Waldenström's macroglobulinemia}} | {{Waldenström's macroglobulinemia}} | ||
{{CMG}}{{AE}}{{MGS}} | {{CMG}}{{AE}}{{S.M.}}{{MGS}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:16, 14 February 2019
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia surgery On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia surgery |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Mirdula Sharma, MBBS [3]
Overview
Surgery is not the first-line treatment option for patients with Waldenström macroglobulinemia. Stem cell transplant is usually reserved for patients with either relapse or refractory Waldenström macroglobulinemia.
Surgery
- Stem cell transplant is usually reserved for patients when either lymphoma comes back (recurs/relapses) after treatment or doesn’t respond to other treatments (called refractory disease).[1]
- Many people with lymphoplasmacytic lymphoma are older or may not be in good health, so a stem cell transplant may not be a good treatment option for them.
References
- ↑ Waldenström's macroglobulinemia: prognosis and management. Blood Cancer Journal (2015) http://www.nature.com/bcj/journal/v5/n3/full/bcj201528a.html Accessed on November 13, 2015